Instil Bio (TIL) Acción Precio

Instil Bio Inc is a clinical-stage biopharmaceutical company headquartered in Dallas, Texas. The company went public via an IPO on March 19, 2021, and currently employs 150 full-time staff. Instil Bio focuses on developing cell therapy treatments, particularly autologous tumor infiltrating lymphocyte (TIL) therapies for cancer patients. The company's lead product candidate, ITIL-168, is an autologous TIL therapy being developed for advanced melanoma, specifically for patients whose cancer has relapsed or become refractory to PD-1 inhibitors. Instil Bio is also advancing a class of genetically engineered TIL therapies through its Co-Stimulatory Antigen Receptor (CoStAR) platform. This platform is used to develop ITIL-306, a lead CoStAR-TIL product candidate that expresses a CoStAR molecule targeting folate receptor alpha (FOLR1), a tumor-associated antigen found in various solid tumors including ovarian, uterine, non-small cell lung cancer, and renal cancers. The company's pipeline includes these two primary candidates, ITIL-168 and ITIL-306, with ITIL-168 initially targeting advanced melanoma and ITIL-306 targeting multiple solid tumor types through FOLR1 recognition. Instil Bio operates as a clinical-stage company with no specified industry or sector classification in the provided data. The company maintains a website at instilbio.com for further information on its research and development activities.